In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Werewolf Therapeutics (HOWL – Research Report), with a price target of $15.00.
Andres Y. Maldonado has given his Buy rating due to a combination of factors related to the promising potential of Werewolf Therapeutics’ WTX-124. The company is expected to present initial first-in-human clinical data from the ongoing Phase 1/1b study of WTX-124 during SITC ’23. Maldonado believes that this early read-out could contribute to de-risking the INDUKINE platform, considering its potential to enhance the therapeutic window and safety of IL-2 therapy. He also suggests that the comparison with previous Phase 1 studies could provide investors with clear benchmarks of WTX-124’s improved profile.
Maldonado does not anticipate full efficacy results from the Phase 1/1b study, but he does hope to see some positive trends. He provides context by mentioning that aldesleukin, the first approved IL-2, was one of the earliest immunotherapies approved for advanced renal cell carcinoma and melanoma treatment. The approval was based on overall response rates of 15% and 16%, respectively. Additionally, the existing data on aldesleukin’s usage in the era of checkpoint inhibitors indicates even better performance than its original FDA approval. Maldonado believes that this information is crucial for understanding new IL-2 therapy data and forms the basis of investor arguments towards the classes’ risk/reward profile.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Werewolf Therapeutics (HOWL) Company Description:
Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
Read More on HOWL:
- Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
- Werewolf Therapeutics to Participate in Upcoming Investor Conferences
- Nvidia upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls
